BRPI0821894A2 - Pharmaceutically acceptable phosphorylation state modulator of at least one enzyme and / or enzyme complex, or subunits thereof, in mitochondria of diseased cells of warm-blooded animals, including humans, method of modulating at least one enzyme or enzyme complex , or a subunit thereof, in a patient having a disease, condition, or syndrome including a change in the phosphorylation state of at least one enzyme and / or an enzyme complex, or a subunit thereof, and method to diagnose and predict benefit in a patient who has symptoms of a disease, condition, or syndrome that includes a change in the phosphorylation state of at least one enzyme and / or enzyme complex, or a subunit thereof - Google Patents

Pharmaceutically acceptable phosphorylation state modulator of at least one enzyme and / or enzyme complex, or subunits thereof, in mitochondria of diseased cells of warm-blooded animals, including humans, method of modulating at least one enzyme or enzyme complex , or a subunit thereof, in a patient having a disease, condition, or syndrome including a change in the phosphorylation state of at least one enzyme and / or an enzyme complex, or a subunit thereof, and method to diagnose and predict benefit in a patient who has symptoms of a disease, condition, or syndrome that includes a change in the phosphorylation state of at least one enzyme and / or enzyme complex, or a subunit thereof

Info

Publication number
BRPI0821894A2
BRPI0821894A2 BRPI0821894-3A BRPI0821894A BRPI0821894A2 BR PI0821894 A2 BRPI0821894 A2 BR PI0821894A2 BR PI0821894 A BRPI0821894 A BR PI0821894A BR PI0821894 A2 BRPI0821894 A2 BR PI0821894A2
Authority
BR
Brazil
Prior art keywords
enzyme
subunit
phosphorylation state
enzyme complex
complex
Prior art date
Application number
BRPI0821894-3A
Other languages
Portuguese (pt)
Inventor
Robert Shorr
Robert Rodriguez
Paul Bingham
Laka W Boteju
Zuzana Zachar
Original Assignee
Robert Shorr
Robert Rodriguez
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Robert Shorr, Robert Rodriguez filed Critical Robert Shorr
Publication of BRPI0821894A2 publication Critical patent/BRPI0821894A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
BRPI0821894-3A 2008-04-04 2008-04-04 Pharmaceutically acceptable phosphorylation state modulator of at least one enzyme and / or enzyme complex, or subunits thereof, in mitochondria of diseased cells of warm-blooded animals, including humans, method of modulating at least one enzyme or enzyme complex , or a subunit thereof, in a patient having a disease, condition, or syndrome including a change in the phosphorylation state of at least one enzyme and / or an enzyme complex, or a subunit thereof, and method to diagnose and predict benefit in a patient who has symptoms of a disease, condition, or syndrome that includes a change in the phosphorylation state of at least one enzyme and / or enzyme complex, or a subunit thereof BRPI0821894A2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2008/004410 WO2009123597A1 (en) 2008-04-04 2008-04-04 Pharmaceutical composition

Publications (1)

Publication Number Publication Date
BRPI0821894A2 true BRPI0821894A2 (en) 2015-07-21

Family

ID=41135840

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0821894-3A BRPI0821894A2 (en) 2008-04-04 2008-04-04 Pharmaceutically acceptable phosphorylation state modulator of at least one enzyme and / or enzyme complex, or subunits thereof, in mitochondria of diseased cells of warm-blooded animals, including humans, method of modulating at least one enzyme or enzyme complex , or a subunit thereof, in a patient having a disease, condition, or syndrome including a change in the phosphorylation state of at least one enzyme and / or an enzyme complex, or a subunit thereof, and method to diagnose and predict benefit in a patient who has symptoms of a disease, condition, or syndrome that includes a change in the phosphorylation state of at least one enzyme and / or enzyme complex, or a subunit thereof

Country Status (10)

Country Link
EP (1) EP2268278A4 (en)
JP (1) JP2011516473A (en)
KR (1) KR20110025168A (en)
CN (1) CN102056605A (en)
AU (1) AU2008354009A1 (en)
BR (1) BRPI0821894A2 (en)
CA (1) CA2720396A1 (en)
IL (1) IL208387A0 (en)
MX (1) MX2010010867A (en)
WO (1) WO2009123597A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX343847B (en) 2010-07-08 2016-11-24 Wrigley W M Jun Co Chewing gum containing a cross-linked gelatin matrix gum base.
US9421234B2 (en) * 2011-05-20 2016-08-23 Nutramax Laboratories, Inc. Orally administrable compositions comprising avocado/soybean unsaponifiables and lipoic acid and methods of administration
JP6253596B2 (en) * 2012-02-16 2017-12-27 ザ ペン ステイト リサーチ ファンデーション Acyl coenzyme A: a method for identifying an inhibitor of expression, function or activity of lysocardiolipin acyltransferase 1 (ALCAT1)
US20150322103A1 (en) * 2012-12-19 2015-11-12 Cornerstone Pharmaceuticals, Inc. Pharmaceutical compounds
AU2014398232B2 (en) 2014-06-19 2019-11-28 Rafael Pharmaceuticals, Inc. Pharmaceutical compounds
WO2015195071A1 (en) 2014-06-19 2015-12-23 Robert Shorr Pharmaceutical compounds
CN110590624B (en) * 2019-09-26 2021-02-26 苏州富士莱医药股份有限公司 Preparation method of lipoic acid derivative 8- (ethyl disulfide) -6- (phenyl disulfide) caprylic acid
WO2023012305A1 (en) * 2021-08-04 2023-02-09 Cytacoat Ab Disulfide compounds as medicaments

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2853497A (en) * 1953-12-04 1958-09-23 Merck & Co Inc 6, 8-bis (hydrocarbon substituted mercapto) 5-hydroxycaprylic acids and delta-lactones thereof
US2789991A (en) * 1954-05-20 1957-04-23 American Cyanamid Co Substituted disulfones
JPS61198148A (en) * 1985-01-29 1986-09-02 Fuji Photo Film Co Ltd Silver halide photographic sensitive material
GB9618934D0 (en) * 1996-09-11 1996-10-23 Univ London Inositol phosphoglycans for therapeutic use in the treatment of diabetes and obesity
KR101085210B1 (en) * 1998-03-20 2011-11-21 커먼웰쓰 사이언티픽 앤드 인더스트리얼 리서치 오가니제이션 Control of gene expression
FR2777001B1 (en) * 1998-04-01 2000-06-09 Cird Galderma 6,8-DIMERCAPTOOCTANOIC ACID DERIVATIVES SUBSTITUTED IN 6-S AND / OR 8-S BY RADICAL (3-METHYLTHIOPROPANOYL) AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CANCER TUMORS
WO2000024734A1 (en) * 1998-10-26 2000-05-04 The Research Foundation Of State University Of New York Lipoic acid derivatives and their use in treatment of disease
DE19904794A1 (en) * 1999-02-05 2000-08-10 Biotechnolog Forschung Gmbh Methods for improving the primary metabolism of mammalian cell lines
US6284786B1 (en) * 1999-02-16 2001-09-04 The Center For The Improvement Of Human Functioning, Int'l., Inc. Treatment of cancer using lipoic acid in combination with ascorbic acid
AR042572A1 (en) * 1999-04-02 2005-06-29 Sod Conseils Rech Applic DERIVATIVES OF LIPOIC ACID, PROCEDURE FOR THE PREPARATION, MEDICINES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND USE OF SUCH DERIVATIVES FOR THE PREPARATION OF THE REFERRED MEDICATIONS
IT1312060B1 (en) * 1999-04-09 2002-04-04 Antibioticos Spa USE OF ALPHA LIPOIC ACID IN ANTIMETASTATIC TREATMENT.
AU2001260309A1 (en) * 2000-05-19 2001-12-03 F.Hoffmann-La Roche Ag A process for determining the tumoricidal potential of a sample by the use of a nucleic acid which is downregulated in human tumor cells
WO2006119355A2 (en) * 2005-05-03 2006-11-09 Albert Einstein College Of Medicine Of Yeshiva University Mammalian hypothalamic nutrient modulation of glucose metabolism
WO2007072219A2 (en) * 2005-09-21 2007-06-28 Aurelium Biopharma Inc. Alpha enolase-directed diagnostics and therapeutics for cancer and chemotherapeutic drug resistance
US20070212360A1 (en) * 2006-01-17 2007-09-13 Denko Nicholas C Modulation of mitochondrial oxygen consumption for therapeutic purposes
NZ580973A (en) * 2007-04-18 2011-10-28 Cornerstone Pharmaceuticals Inc Pharmaceutical formulations containing lipoic acid derivatives
EP2139321B1 (en) * 2007-04-18 2013-11-06 Cornerstone Pharmaceuticals, Inc. Lipoic acid derivatives
AU2008352076A1 (en) * 2008-03-04 2009-09-11 Robert Rodriguez Modulation of enzymatic structure, activity, and/or expression level

Also Published As

Publication number Publication date
WO2009123597A1 (en) 2009-10-08
MX2010010867A (en) 2011-05-25
IL208387A0 (en) 2010-12-30
KR20110025168A (en) 2011-03-09
EP2268278A4 (en) 2011-11-09
AU2008354009A1 (en) 2009-10-08
CN102056605A (en) 2011-05-11
EP2268278A1 (en) 2011-01-05
JP2011516473A (en) 2011-05-26
CA2720396A1 (en) 2009-10-08

Similar Documents

Publication Publication Date Title
BRPI0821894A2 (en) Pharmaceutically acceptable phosphorylation state modulator of at least one enzyme and / or enzyme complex, or subunits thereof, in mitochondria of diseased cells of warm-blooded animals, including humans, method of modulating at least one enzyme or enzyme complex , or a subunit thereof, in a patient having a disease, condition, or syndrome including a change in the phosphorylation state of at least one enzyme and / or an enzyme complex, or a subunit thereof, and method to diagnose and predict benefit in a patient who has symptoms of a disease, condition, or syndrome that includes a change in the phosphorylation state of at least one enzyme and / or enzyme complex, or a subunit thereof
BRPI0820967A2 (en) Use of a composition, pharmaceutical composition and method for treating, ameliorating or prophylaxis of the symptoms of an inflammatory disease.
BR112014004685A2 (en) methods and apparatus for determining power line conditions
BRPI0816097A2 (en) pharmaceutical composition, method for treating erythema in a patient with rosacea, and, use of a composition.
BR112015003332A2 (en) compound, pharmaceutical composition, use of the compound and method for treating a rorgammat-mediated disease or condition in a patient
EA202091999A3 (en) APPLICATION OF DPP IV INHIBITORS
BR112013033943A2 (en) system for use with one or more affiliated patient data sources, methods for updating a patient-specific guidance data set, updating a plurality of patient interface device databases, operating a patient interface device, administering data in a system and patient interface device
BR112012031389A2 (en) Method to Predict Clinical Outcomes for Melanoma Patients Using Circulating Blood Melanoma Cells
BRPI0821895A2 (en) PHARMACEUTICAL COMPOSITION, METHOD OF TREATMENT OR PREVENTION OF A DISEASE, A CONDITION AND SYMPTOMS OF THE SAME IN HOT BLOOD ANIMALS, INCLUDING HUMAN BEINGS, METHOD FOR PREPARATION OF THE PHARMACEUTICAL COMPOSITION, METHOD DIAGNOSIS
BRPI1009381A2 (en) compounds, pharmaceutical composition, method for treating disease or condition associated with trap1 function in subject in need thereof and use of compounds and pharmaceutical composition
BRPI0909352A2 (en) therapeutic device and which may be contacted with a patient to therapeutically cool the patient, system to therapeutically regulate a patient's body temperature, therapeutic method to regulate a patient's body temperature method to therapeutically cool the body temperature of a A patient wrapper and wrapper.
BR112013033309A2 (en) method for treating or preventing at least one inflammatory condition in a patient, method for inhibiting liver damage in a patient at risk of chemical liver damage from prescribed drugs or drugs of abuse, method for inhibiting nkt type i cell mediated tissue damage in a patient, method for inhibiting nkt type i cell activation, method for inhibiting nkt type i cell activation in a patient with an inflammatory disease, and method for inhibiting myeloid cell release in a patient's liver
BRPI1013560A2 (en) methods to aid in the prognosis of inflammatory bowel disease, and to predict the likelihood that an individual diagnosed with inflammatory bowel disease will respond to a therapeutic agent of inflammatory bowel disease
BRPI0716555A2 (en) Methods to predict the likelihood that a patient is a candidate for treatment with a ret drug will respond to said treatment, and to treat a patient, mutant direct primer, and diagnostic kit.
BRPI0813456A2 (en) COMPOSITION, USE OF THE SAME, PHARMACEUTICAL COMPOSITION, AND METHODS TO TREAT A MAMMAL WITH A DISORDER AND DISEASE
BRPI0918398A2 (en) Method for diagnosing a physiological abnormality in a patient, System for diagnosing a physiological abnormality in a patient, Catheter and Device for diagnosing a physiological abnormality in a patient
BRPI0814339A2 (en) pharmaceutical composition, kit for the preparation of the pharmaceutical composition, conjugate and methods for in vivo optical imaging of the mammalian body, and for the detection, stabilization, diagnosis, monitoring of disease progress or monitoring of the treatment of a disease state. mammal body
BR112017014419A2 (en) diagnosis and treatment of incipient diabetes
BRPI0812597A2 (en) SALT, PHARMACEUTICAL COMPOSITION, METHODS FOR TREATMENT, PREVENTION OR IMPROVEMENT OF ONE OR MORE SYMPTOMS OF A CRTH2 MEDIATED DISEASE, AN EOSINOPHILY DISEASE, A BASOPHYL DISEASE DISEASE, AND A INFLAMMATORY DISEASE SALT PREPARATION
CY1121852T1 (en) FORMULATIONS AND METHODS OF PREPARING FORMULATIONS FOR USE IN COLON CLEANSING
BRPI0810917A2 (en) EXAMINATION METHODS FOR COMPULSORY INTERACTION USING ORIGINAL MICROPARTMENT GAMES AND GAMES
Reuther et al. Effect of return to overuse activity following an isolated supraspinatus tendon tear on adjacent intact tendons and glenoid cartilage in a rat model
BRPI0914921A2 (en) methods for diagnosing chronic obstructive pulmonary disease in a human patient or the risk of a human patient developing chronic obstructive pulmonary disease, for discriminating between stage i / ii chronic obstructive pulmonary disease and stage iii / iv chronic obstructive pulmonary disease, and for monitoring progress of chronic obstructive pulmonary disease in a human patient
BRPI0912706A2 (en) use of dronedarone for the preparation of a drug for the treatment of patients with arrhythmia and an increase in creatinine level due to dronedarone administration
BRPI0821176A2 (en) phosphorylation state modulator of at least one enzyme complex, method for modulating the pdh complex in a patient presenting a disease, condition, or syndrome, and method for diagnosing and predicting benefit in a patient presenting symptoms of a disease, condition , or syndrome caused by a change in the structure and / or activity of the pdh complex

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]